Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
(NASDAQ:LYEL) SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation CAR T-cell therapies...
When are interim data readouts expected, and how might those milestones impact Lyell's stock volatility and short‑term trading opportunities?
What are the expectations for market share and pricing if ronde‑cel demonstrates superiority over liso‑cel and axi‑cel in relapsed/refractory large B‑cell lymphoma?
How will the initiation of the PiNACLE‑H2H Phase 3 trial affect Lyell Immunopharma's near‑term cash burn and funding needs?
4 days ago